Side effects of lunesta
Pro Research Analysisby 
Searched over 200M research papers
Side Effects of Lunesta (Eszopiclone)
Common Side Effects: Dysgeusia and Taste Disturbances
One of the most frequently reported side effects of Lunesta (eszopiclone) is dysgeusia, a condition characterized by a distorted sense of taste. In a double-blind study, 66% of female subjects and 53% of male subjects reported experiencing dysgeusia, primarily described as a bitter or metallic taste . The intensity and duration of these taste disturbances were found to be more pronounced in women and were stronger in the morning compared to the evening. Additionally, the severity of dysgeusia was positively correlated with the levels of the drug in the blood and saliva .
Neuropsychiatric Effects: Memory Impairment and Behavioral Changes
Lunesta has been associated with mild, transient memory impairment in some patients . Moreover, a variety of abnormal thinking and behavioral changes have been reported, including decreased inhibition, aggressiveness, extroversion, bizarre behavior, agitation, hallucinations, and depersonalization . These neuropsychiatric symptoms can occur unpredictably and may be dose-related, emphasizing the importance of using the lowest effective dose, especially in elderly patients .
CNS Depressant Effects: Coordination and Alertness Impairment
As a central nervous system (CNS) depressant, Lunesta can impair motor coordination and mental alertness. Patients are advised to take the medication immediately before bedtime to minimize these effects. Activities requiring full mental alertness or motor coordination, such as driving or operating machinery, should be avoided after taking Lunesta . The drug's CNS depressant effects can be exacerbated when taken with other CNS depressants, including alcohol, necessitating caution and possible dose adjustments .
Potential for Dependence and Withdrawal Symptoms
Although Lunesta is effective for treating insomnia without evidence of tolerance, dependence, or abuse over a six-month period, rapid dose reduction or abrupt discontinuation can lead to withdrawal symptoms similar to those associated with other CNS depressants Kirk2005Uslaner2013. Therefore, it is crucial to follow a healthcare provider's guidance when discontinuing the medication to mitigate withdrawal risks.
Special Considerations: Elderly and Patients with Concomitant Illnesses
Elderly patients and those with concomitant illnesses may experience heightened sensitivity to the sedative effects of Lunesta. For these populations, a lower starting dose of 1 mg is recommended to reduce the risk of impaired motor and cognitive performance . Additionally, caution is advised when prescribing Lunesta to patients with compromised respiratory function or severe hepatic impairment, as these conditions can affect the drug's metabolism and systemic exposure .
Conclusion
Lunesta (eszopiclone) is an effective treatment for insomnia but comes with several potential side effects. Dysgeusia, neuropsychiatric symptoms, CNS depressant effects, and the risk of dependence and withdrawal are notable concerns. Special care should be taken when prescribing Lunesta to elderly patients and those with concomitant illnesses. Always consult a healthcare provider for personalized advice and follow their recommendations closely to minimize risks.
Sources and full results
Most relevant research papers on this topic
Orexin Receptor Antagonists Differ from Standard Sleep Drugs by Promoting Sleep at Doses That Do Not Disrupt Cognition
Dual orexin receptor antagonists (DORA-22) promote sleep at lower doses without disrupting cognition, offering a potential alternative to current insomnia treatments without cognitive side effects.
The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a randomized placebo-controlled trial.
Eszopiclone increases sleep spindles, which may improve sleep-dependent memory consolidation in schizophrenia patients.
Eszopiclone stimulates the hypothalamo-pituitary-adrenal axis in the rat.
Eszopiclone stimulates the hypothalamo-pituitary-adrenal axis in rats, differing from benzodiazepine-type drugs in their differential effects on this system.
A New Class of Hypnotic Compounds for the Treatment of Insomnia: The Dual Orexin Receptor Antagonists
Dual orexin receptor antagonists (DORAs) show promise in improving sleep latency and quantity for insomnia patients, with potential for better tolerability and less cognitive impairment than GABAA receptor allosteric modulators.
DOI